I

    iSpecimen Inc (ISPC)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $1.54
    +0.00 (+0.00%)

    Market Cap: $3.88M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(5/13)
    Avg Surprise
    -55.06%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 4
    		$-0.98N/AN/ABeat-133.3%
    Mar 26
    Reported Apr 1
    		$-6.66N/AN/ABeat-838.7%
    Dec 25
    Reported Mar 12
    		$-23.59N/AN/ABeat-1026.0%
    Sep 25
    Reported Nov 17
    		$-0.48$0.00N/AMiss+99.7%
    Jun 25
    Reported Aug 14
    		$-0.42N/AN/ABeat+99.8%
    Mar 25
    Reported Apr 14
    		$-0.71$-0.31-129.03%Miss-121.9%
    Sep 24
    Reported Nov 6
    		$-2.10$-0.29-622.55%Miss+98.9%
    Jun 24
    Reported Aug 6
    		$-152.00$-224.00+32.14%Beat+51.3%
    Mar 24
    Reported May 6
    		$-256.00$-216.00-18.52%Miss-18.5%
    Dec 23
    Reported Mar 13
    		$-0.32$-0.24-33.33%Miss-33.3%
    Sep 23
    Reported Nov 1
    		$-184.00$-280.00+34.29%Beat+34.3%
    Jun 23
    Reported Aug 2
    		$-312.00$-240.00-30.00%Miss-30.0%
    Mar 23
    Reported May 3
    		$-216.00$-256.00+15.63%Beat+0.0%
    Dec 22
    Reported Mar 14
    		$-0.24$-0.37+35.14%Beat+99.8%
    Sep 22
    Reported Nov 8
    		$-280.00$-272.00-2.94%Miss-127172.7%
    Jun 22
    Reported Aug 4
    		$-240.00$-220.00-9.09%Miss-114185.7%
    Mar 22
    Reported May 10
    		$-216.00$-202.67-6.58%Miss-86300.0%
    Dec 21
    Reported Feb 17
    		$-136.00$-168.00+19.05%Beat-71478.9%
    Sep 21
    Reported Nov 4
    		$-0.22N/AN/ABeat+87.1%
    Jun 21
    Reported Aug 10
    		$-0.21$0.00N/AMiss+84.2%
    Mar 21
    Reported Jun 17
    		$-0.25$0.00N/AMiss-34.4%
    Dec 20
    Reported Jan 20
    		$-0.19$0.00N/AMiss+89.1%
    Sep 20
    Reported Dec 31
    		$-1.70$0.00N/AMiss-18.1%
    Jun 20
    Reported Sep 30
    		$-1.33$0.00N/AMiss+40.8%
    Mar 20
    Reported Jun 29
    		$-0.19$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-1.75$0.00N/AMiss-
    Sep 19
    Reported Dec 31
    		$-1.44$0.00N/AMiss-
    Jun 19
    Reported Sep 30
    		$-2.25$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.05EV/EBITDA0.43x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-897.00%
    ROE-968.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.82xQuick Ratio0.82x
    Trading Statistics
    Beta1.64Avg Volume528.04K
    52-Week High$127.2052-Week Low$1.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.82
    SMA 20$2.01
    SMA 50$2.20
    SMA 200$8.23
    EMA 10$1.75
    EMA 20$1.91
    EMA 50$2.38
    EMA 200$10.93

    MACD

    Line: -0.19Signal: -0.14Hist: -0.05

    ADX

    ADX: 23.4+DI: 13.8-DI: 32.4

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down84.0
    PSAR$2.28

    Bollinger Bands

    Upper Band$2.65
    Lower Band$1.36
    %B Position6443%(Upper)
    Band Width0.14

    RSI (14-Day)

    Neutral
    32.5

    Momentum Oscillators

    Stoch %K13.4
    Stoch %D15.9
    Williams %R-88.2
    ROC (10d)-28.4%
    Momentum-0.61
    CCI (20d)-107.1
    MFI (14d)4.4

    Volatility Measures

    ATR (14d)$0.21(13.6%)
    StdDev (20d)0.32
    Hist Vol127.4%(High)

    Volume Flow

    VWAP$1.55
    OBV556.8M
    AD Line624.6B
    CMF (20d)-0.448

    Volume Metrics

    Avg Vol (20d)552.9K
    Vol Ratio0.1x(Low)
    VWMA (20d)$2.12

    Pivot Points

    R3$1.70
    R2$1.65
    R1$1.60
    Pivot Point$1.55
    S1$1.50
    S2$1.45
    S3$1.40

    Advanced Oscillators

    TSI-24.99
    Ultimate Osc38.4
    KST-147.23

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$151,940$156,009$51,761$106,592$713,135$1.06M$1.48M$2.66M$2.86M$2.29M$2.58M$2.78M
    Cost of Revenue$83,290$84,410$598,839$204,593$444,177$657,279$1.32M$1.55M$1.42M$1.00M$1.43M$1.39M
    Gross Profit$68,650$71,599$-547,078$-98,001$268,958$400,231$151,352$1.11M$1.44M$1.29M$1.15M$1.39M
    Operating Expenses$1.43M$2.61M$2.14M$2.73M$2.09M$2.04M$5.99M$2.81M$3.62M$4.29M$4.02M$3.58M
    R&D$37,511$34,017$31,835$22,373$99,090$93,681$117,566$84,972$137,511$197,839$277,621$186,176
    SG&A$442,508$680,415$901,130$864,061$948,376$758,666$2.02M$892,712$1.06M$2.10M$1.26M$1.10M
    Operating Income$-1,362,986$-2,538,403$-2,687,882$-2,830,222$-1,821,426$-1,638,389$-5,840,456$-1,705,404$-2,181,665$-3,000,520$-2,871,023$-2,194,080
    Interest Income$270$291$271$291$398$2,788$3,237$1,235$9,163$30,498$47,243$67,362
    Interest Expense$0$1,253$1,119$-2,067$-9,620$20,486$203,771$7,364$4,474$4,465$219,250$4,465
    Income Before Tax$-1,362,811$-2,275,221$-5,001,245$-2,780,648$-1,047,243$-1,658,396$-6,046,811$-1,439,853$-2,109,024$-2,902,117$-3,072,961$-2,111,101
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,362,811$-2,275,221$-5,001,245$-2,780,648$-1,047,243$-1,658,396$-6,046,811$-1,439,853$-2,109,024$-2,902,117$-3,072,961$-2,111,101
    EBITDA$-1,161,615$-2,138,314$-4,592,666$-2,325,276$-624,529$-1,207,989$-5,302,686$-886,500$-1,506,969$-2,331,461$-2,173,326$-1,699,159
    EBIT$-1,363,081$-2,274,259$-5,000,397$-2,783,006$-1,057,261$-1,640,698$-5,846,277$-1,433,724$-2,113,713$-2,928,150$-2,900,954$-2,173,998
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ISPC

    News

    iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

    iSpecimen Inc. successfully completed a large-scale international cancer research project, shipping hundreds of cancer blood specimens within three weeks of receiving the purchase order. The company leveraged its global network of healthcare and research partners to efficiently source, collect, and fulfill the time-sensitive request. This achievement highlights iSpecimen's focus on accelerating medical discovery by providing rapid access to human biospecimens.

    TMX Newsfile•8/20/26•
    Bullish

    iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks

    iSpecimen (Nasdaq: ISPC) successfully completed a large-scale international cancer research order, shipping hundreds of cancer blood specimens within three weeks. The company utilized its global network of healthcare institutions and partners to rapidly source and fulfill specialized cancer biospecimens, including FFPE and flash-frozen tissue. Despite this operational success, the market reacted negatively, with ISPC stock declining 15.42% following the news.

    Stock Titan•8/20/26•
    Bearish

    iSpecimen | 10-Q: Q2 2026 Earnings Report

    This document is the 10-Q filing for iSpecimen's Q2 2026 earnings report. It contains the financial and operational details required for quarterly reporting to the SEC.

    Moomoo•8/15/26•
    Neutral

    iSpecimen (ISPC) revenue drops to $308K as losses deepen and cash burns

    iSpecimen Inc. (ISPC) reported a significant decline in revenue to $308K for the first half of 2026, down from $1.77 million a year earlier, alongside a deepened net loss of $3.64 million. The company disclosed substantial doubt about its ability to continue as a going concern due to negative working capital and continued reliance on external financing, despite implementing cost-cutting measures and securing recent equity funding. Operating cash flow for the first half of 2026 was negative $4.05 million, though partially offset by private placements and an August 2026 offering.

    Stock Titan•8/14/26•
    Bearish

    iSpecimen settles arbitration with WestPark Capital for $97,500, ends agreements

    iSpecimen Inc. has settled an arbitration dispute with WestPark Capital, Inc., agreeing to pay $97,500 to resolve all claims related to prior investment banking engagements. The settlement terminates previous agreements between the parties and includes mutual general releases, with both sides bearing their own legal costs. iSpecimen expects to record the payment as a charge in the quarter ending September 30, 2026.

    Investing.com Nigeria•8/11/26•
    Neutral

    Frequently Asked Questions About ISPC

    Does ISPC pay dividends?
    iSpecimen Inc (ISPC) does not currently pay a regular dividend.
    What is ISPC's market cap?
    iSpecimen Inc (ISPC) has a market capitalization of $3.88M with a current stock price of $1.54.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In